SCHEMBL569075

SCHEMBL569075

N[C@H]1CCCC[C@H]1NC(=O)P(=O)(O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 13/20 1.00
CA12 O43570 9/20 1.00
CA1 P00915 9/20 1.00
CA2 P00918 9/20 1.00
CA9 Q16790 9/20 1.00
MMP8 P22894 8/20 1.00
MMP1 P03956 6/20 1.00
MMP9 P14780 4/20 1.00
MMP3 P08254 3/20 1.00
MMP13 P45452 1/20 1.00
ANPEP P15144 1/20 0.47
ERAP2 Q6P179 1/20 0.47
HDAC4 P56524 1/20 0.36
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4854279 1.00 MMP2 (1.00) MMP2CA12CA1CA2CA9
SCHEMBL4861903 1.00 MMP2 (1.00) MMP2CA12CA1CA2CA9
SCHEMBL4855712 1.00 MMP2 (1.00) MMP2CA12CA1CA2CA9
SCHEMBL569074 1.00 MMP2 (1.00) MMP2CA12CA1CA2CA9
SCHEMBL530223 0.75 MMP2 (0.60) MMP2CA12CA1CA2CA9
SCHEMBL4285508 0.75 MMP2 (0.60) MMP2CA12CA1CA2CA9
SCHEMBL2940123 0.75 MMP2 (0.60) MMP2CA12CA1CA2CA9
SCHEMBL14534604 0.75 MMP2 (0.60) MMP2CA12CA1CA2CA9
SCHEMBL1987041 0.75 MMP2 (0.60) MMP2CA12CA1CA2CA9
SCHEMBL2938943 0.75 MMP2 (0.60) MMP2CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345033-B2 Carbamoyl-and thiocarbamoyl-phosphonates and pharmaceutical compositions comprising them YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2008-03-18 US claimed
US-20060111328-A1 Carbamoyl-and thiocarbamoyl-phosphonates and pharmaceutical compositions comprising them YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-05-25 US claimed
EP-1611143-A2 NEW CARBAMOYL-AND THIOCARBAMOYL-PHOSPHONATES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-01-04 EP claimed
WO-2004089962-A2 NEW CARBAMOYL-AND THIOCARBAMOYL-PHOSPHONATES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2004-10-21 WO claimed
US-20250090586-A1 METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) 2025-03-20 US disclosed
US-12076347-B2 Methods for production of platelets from pluripotent stem cells and compositions thereof ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) 2024-09-03 US disclosed
US-11971402-B2 Methods and reagents for determination and treatment of organotropic metastasis CORNELL UNIVERSITY (US) 2024-04-30 US disclosed
US-20230067928-A1 METHODS FOR PROGNOSING AND PREVENTING METASTATIC LIVER DISEASE UNIV CORNELL (US) 2023-03-02 US disclosed
US-20230028239-A1 METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) 2023-01-26 US disclosed
US-11400118-B2 Methods for production of platelets from pluripotent stem cells and compositions thereof ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) 2022-08-02 US disclosed
US-11397182-B2 Methods for prognosing and preventing metastatic liver disease CORNELL UNIVERSITY (US) 2022-07-26 US disclosed
CN-114558032-A Method for preparing platelets from pluripotent stem cells and composition thereof 安斯泰来再生医药协会 2022-05-31 CN disclosed
US-20120035140-A1 CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2012-02-09 US disclosed
EP-2393495-A1 CARJBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) 2011-12-14 EP disclosed
WO-2010089752-A1 CARJBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2010-08-12 WO disclosed
US-7345033-B2 Carbamoyl-and thiocarbamoyl-phosphonates and pharmaceutical compositions comprising them YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2008-03-18 US disclosed
US-7345033-B2 Carbamoyl-and thiocarbamoyl-phosphonates and pharmaceutical compositions comprising them YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2008-03-18 US disclosed
US-20060111328-A1 Carbamoyl-and thiocarbamoyl-phosphonates and pharmaceutical compositions comprising them YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-05-25 US disclosed
EP-1611143-A2 NEW CARBAMOYL-AND THIOCARBAMOYL-PHOSPHONATES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-01-04 EP disclosed
WO-2004089962-A2 NEW CARBAMOYL-AND THIOCARBAMOYL-PHOSPHONATES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035140-A1 CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF MMP9, MMP26, MMP25 MMP2 10/4885CA12 307/4885CA1 247/4885
US-20060111328-A1 Carbamoyl-and thiocarbamoyl-phosphonates and pharmaceutical compositions comprising them P2RY1, PLCB1, PLCB3 MMP2 4697/4885CA12 1139/4885CA1 841/4885
US-20230028239-A1 METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF THPO, PDGFRA, PDGFRB MMP2 3559/4885CA12 3978/4885CA1 4210/4885
US-11400118-B2 Methods for production of platelets from pluripotent stem cells and compositions thereof THPO, PDGFRA, PDGFRB MMP2 3559/4885CA12 3978/4885CA1 4210/4885
US-20250090586-A1 METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF THPO, PDGFRA, PDGFRB MMP2 3559/4885CA12 3978/4885CA1 4210/4885
US-12076347-B2 Methods for production of platelets from pluripotent stem cells and compositions thereof THPO, PDGFRA, PDGFRB MMP2 3559/4885CA12 3978/4885CA1 4210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.